Alessa gets FDA backing for pivotal Enolen prostate cancer trial

Alessa Therapeutics said July 1, 2026, that the FDA backed its planned Phase 3 design for Enolen, saying one study with progression-free survival as the primary endpoint can support an NDA. The company expects to start the pivotal trial in mid-2027, a step that could move the localized prostate cancer therapy closer to a front-line treatment path.

Why it matters: - The FDA feedback gives Alessa Therapeutics a clearer path to a potential New Drug Application for Enolen in low- to intermediate-risk localized prostate cancer. - The agency’s view reduces development risk by indicating one pivotal trial may be enough. - The decision could speed progress for a treatment designed to avoid the side effects of systemic anti-androgen and testosterone-lowering drugs.

What happened: - Alessa Therapeutics said July 1, 2026, that it received positive feedback from a Type C meeting with the FDA on the planned pivotal Phase 3 trial for Enolen. - The FDA confirmed that a single trial comparing Enolen with active surveillance is sufficient to support an NDA filing. - The FDA also said no additional clinical trials beyond the ongoing Phase 1 study will be required before the pivotal trial. - The agency said no additional non-clinical work will be needed before that study. - Alessa expects to begin the pivotal Phase 3 trial in mid-2027.

The details: - Enolen is Alessa’s lead product candidate for low- to intermediate-risk localized prostate cancer. - The planned pivotal study will use progression-free survival as the primary endpoint. - Cam Gallagher, Alessa’s president and CEO, said the FDA discussions established a clearly defined clinical development pathway for Enolen. - Gallagher said the company believes preclinical and clinical results so far support Enolen as an alternative to active surveillance and more aggressive treatment options. - Pamela Munster, chief scientific advisor and founder of Alessa, said the pathology-based primary endpoint provides a foundation for demonstrating Enolen’s efficacy. - Enolen uses anti-androgen eluting implants containing the FDA-approved prostate cancer drug enzalutamide. - Alessa is studying Enolen in a Phase 1 trial for safety, tolerability and preliminary efficacy in localized sustained delivery of enzalutamide into prostate tumors. - The Phase 1 study launched at the National Cancer Institute and is now enrolling at eight U.S. sites. - The FDA granted Enolen Fast Track designation earlier in 2026.

Between the lines: - The FDA’s response suggests regulators are comfortable with a streamlined development plan for a localized prostate cancer therapy that is trying to show clinical benefit without broad systemic exposure. - A single pivotal trial with a progression-free survival endpoint is a meaningful signal for a program still early in development. - The pathway also reflects the company’s push to position Enolen as a front-line option for men who may want to avoid active surveillance or the side effects of more intensive treatment.

What's next: - Alessa will continue enrolling and following patients in the ongoing Phase 1 trial. - The company plans to expand that study into two additional cohorts as it advances toward Phase 3. - Alessa expects to start the pivotal Phase 3 trial in mid-2027. - If the Phase 3 study is successful, the company could move toward an NDA filing for localized prostate cancer.

The bottom line: - The FDA meeting gives Alessa a clearer, faster regulatory route for Enolen and strengthens the case for a pivotal readout in 2027.